Aesica Appoints Two New Business Development Managers
News Jul 17, 2013
Aesica has appointed Sven Thomas and David Ross as business development managers. Their appointment is the next phase in the company’s international drive to increase sales from its integrated API, formulation development and manufacturing services and they will be responsible for ensuring potential customers are clearly aware of how the company can support their manufacturing and development needs.
Under the new structure, David Ross will focus on the UK, Ireland and Scandinavia whilst Sven Thomas will handle Central and Eastern Europe with a strong emphasis on expanding the level of business from Germany and the growing economies in Eastern Europe.
In combination, three business development managers, Nicholas Micheaud, who has responsibility for South Western Europe, David Ross and Sven Thomas report to Jeremy Drummond, the Sales Director.
Sven Thomas brings a breadth of pharmaceutical manufacturing expertise to the task in hand having previously worked for UCB, whilst David Ross brings wide ranging experience in contract research and contract manufacturing with Patheon, Catalant and Ipsen.
Sven Thomas commented: “I am delighted to take on my new position at Aesica and to play a key role in driving forward our services in the German market, as well as Eastern Europe. Indeed, the fact that we have site facilities geographically situated in Monheim and Zwickau as well as in Italy and the UK, ensures that Aesica is well situated to deliver reliable services to customers from all of Europe.”
He continued: “Moreover, we have a strong pedigree in Germany with over thirty years manufacturing, working on established UCB and Schwarz products at our Zwickau and Monheim sites. We provide a bespoke individualized approach to client servicing and have the flexibility to cater for what are often multiple formulated product needs of each customer.”
David Ross remarked: “I very much look forward to playing a key regional role in driving new business across the UK, Ireland and Scandinavia. The integrated nature, scale and range of our service offering and our track record of transferring in new technologies stand us out in the highly competitive CDMO market place”.
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE